PURPOSE: Animal research and cross-sectional studies suggest that serum lip
id concentrations may influence cognitive function, mood, and behavior, but
few clinical trials have studied these effects.
SUBJECTS AND METHODS: In this double-blind investigation, 209 generally hea
lthy adults with a serum low-density lipoprotein (LDL) cholesterol level of
160 mg/dL or higher were randomly assigned to 6-month treatment with lovas
tatin (20 mg) or placebo. Assessments of neuropsychological performance, de
pression, hostility, and quality of life were conducted at baseline and at
the end of the treatment period. Summary effect sizes were estimated as z s
cores on a standard deviation (SD) scale.
RESULTS: Placebo-treated subjects improved between baseline and posttreatme
nt periods on neuropsychological tests in all five performance domains, con
sistent with the effects of practice on test performance (all P <0.04), whe
reas chose treated with lovastatin improved only on tests of memory recall
(P = 0.03). Comparisons of the changes in performance between placebo- and
lovastatin-treated subjects revealed small, but statistically significant,
differences for tests of attention (z score = 0.18; 95% confidence interval
(CI), 0.06 to 0.31: P = 0.005) and psychomotor speed (z score = 0.17; 95%
Ci, 0.05 to 0.28; P = 0.004) that were consistent with greater improvement
in the placebo group. Psychological well-being, as measured several ways, w
as not affected by lovastatin.
CONCLUSION: Treatment of hypercholesterolemia with lovastatin did not cause
psychological distress or substantially alter cognitive function. Treatmen
t did result in small performance decrements on neuropsychological tests of
attention and psychomotor speed, the clinical importance of which is uncer
tain. (C) 2000 by Excerpta Medica, Inc.